Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide
| Autor: | Bruce Barger, Eric E. Lloyd, William C. Cushman, Joel M. Neutel, Alison Handley |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Fixed-dose combination Urology Blood Pressure 030204 cardiovascular system & hematology Essential hypertension 03 medical and health sciences 0302 clinical medicine Hydrochlorothiazide Azilsartan Internal Medicine medicine Humans 030212 general & internal medicine Azilsartan Medoxomil Diuretics Letters to the Editor Antihypertensive Agents Aged Aged 80 and over Oxadiazoles Olmesartan Medoxomil Dose-Response Relationship Drug business.industry Chlorthalidone Middle Aged medicine.disease Treatment Outcome Tolerability Benzimidazoles Drug Therapy Combination Female Essential Hypertension Cardiology and Cardiovascular Medicine Olmesartan business Angiotensin II Type 1 Receptor Blockers medicine.drug |
| Zdroj: | J Clin Hypertens (Greenwich) |
| ISSN: | 1524-6175 |
| DOI: | 10.1111/jch.13009 |
| Popis: | This 52-week, randomized, open-label study evaluated long-term safety/tolerability of fixed-dose combination azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs fixed-dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hypertension (stage 2; clinic systolic blood pressure 160-190 mm Hg). Initial AZL-M/CLD 40/12.5 mg/d (n=418) or OLM/HCTZ 20/12.5 mg/d (n=419) could be uptitrated during weeks 4 to 52 (AZL-M/CLD to 80/25 mg; OLM/HCTZ to 40/25 mg [United States] or 20/25 mg [Europe]) to meet blood pressure targets. Treatment-emergent adverse events/serious adverse events occurred in 78.5%/5.7% of patients taking AZL-M/CLD vs 76.4%/6.2% taking OLM/HCTZ. The most frequent adverse events were dizziness (16.3% vs 12.6%), blood creatinine increase (21.5% vs 8.6%), headache (7.4% vs 11.0%), and nasopharyngitis (12.2% vs 11.5%). Hypokalemia was uncommon (1.0% vs 0.7%). Greater blood pressure reductions with AZL-M/CLD by week 2 were maintained throughout the study, despite less uptitration (32.3% vs 48.9% with OLM/HCTZ). Fixed-dose combination AZL-M/CLD showed an encouraging benefit-risk profile when used per standard clinical practice in a titrate-to-target strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|